China: Provisional assent for Pfizer's COVID pill - Breaking The News

China: Provisional assent for Pfizer's COVID pill

12 February

1 min read

EPA/ANDREW GOMBERT

China's National Medical Products Administration announced on Saturday it has given provisional approval for the use of Paxlovid, Pfizer Inc.'s oral treatment against COVID-19.

The agency said the pills will be given to adults with symptoms that seem that they could evolve into a riskier case of COVID-19 until the trial is concluded in full.

The vaccine against the virus Pfizer developed with BioNTech Se is currently being examined and considered for approval in China.

coronavirus pfizer

Related Stocks

Pfizer

US attorney allegedly probes tip about Pfizer's vaccine timing

26 March

The United States Attorney's office is investigating a claim by the British pharmaceutical company GSK about the "delayed" announcement of the success of Pfizer's Covid vaccine in 2020, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.According to the report, Pfizer's former employee, Phil Dormitzer, who later became a senior scientist at Pfizer's rival company, GSK, told his colleagues at GSK that Pfizer delayed the...

China's VP He meets with Apple's Cook

24 March

Chinese Vice Premier and Central Financial and Economic Affairs Commission Office Director He Lifeng met with the heads of various major companies from North America to discuss the trade relations between Beijing and the United States, the Asian country's Commerce Ministry (MOFCOM) said in a statement issued on Monday.He met with the leaders of Pfizer Inc., Brookfield Corporation, Mastercard Inc., Cargill Incorporated, Corning Inc., and Apple Inc., with the...

Moderna wins against Biontech, Pfizer in patent dispute

5 March

A Dusseldorf court ruled in favor of Moderna in a patent dispute against Biontech and Pfizer on Tuesday, ordering them to disclose profits and compensate for unauthorized use of patented mRNA technology.Moderna claimed the companies copied innovations it had developed between 2010 and 2016 for their COVID-19 vaccine. Biontech and Pfizer argued they had permission to use the patent until May 5, 2023, based on a statement Moderna issued in 2020....

Vaccine stocks fall after RFK Jr.'s HHS nomination advances

4 February

Shares of vaccine makers, including Moderna, Pfizer, and BioNTech, dipped Tuesday after the Senate Finance Committee advanced Robert F. Kennedy Jr.'s nomination for Health and Human Services secretary.The 14-13 party-line vote moved the controversial pick to the Senate floor. Kennedy, known for his skepticism of vaccines, has drawn sharp criticism for his previous comments on vaccine safety.At 10:41 am ET, Moderna's stock fell 5.11% to $34.68,...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.